Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept study

The inhibiting effects of itraconazole, an antifungal drug on vascular endothelial growth factor (VEGF) have recently been discovered. By inhibiting VEGF, itraconazole has shown potential in clinical trials as anti-cancer treatment. In hereditary hemorrhagic telangiectasia (HHT) patients, VEGF level...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Angiogenesis (London) 2021-05, Vol.24 (2), p.379-386
Hauptverfasser:	Kroon, S., Snijder, R. J., Hosman, A. E., Vorselaars, V. M.M., Disch, F. J.M, Post, M. C., Mager, J. J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Aged Angiogenesis Antiangiogenics Antifungal agents Biomedical and Life Sciences Biomedicine Bleeding Cancer Research Cardiology Cell Biology Clinical trials Epistaxis Epistaxis - drug therapy Female Fungicides Genetic Diseases, Inborn - drug therapy Growth factors Hemoglobin Hemorrhage Hereditary hemorrhagic telangiectasia Humans Itraconazole Itraconazole - administration & dosage Male Middle Aged Mutation Oncology Ophthalmology Oral administration Original Paper Patients Proof of Concept Study Quality of Life Side effects Telangiectasia, Hereditary Hemorrhagic - drug therapy Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!